Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07261254Not ApplicableRecruiting

Integrating Systems and Basic Income: Improving Outcomes for Families of Young Children

Role: collaborator

NCT04466150Phase 4Active Not Recruiting

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Role: collaborator

NCT03641092Not ApplicableRecruiting

CenteringParenting Clinical Intervention on Kindergarten Readiness in Early Childhood

Role: collaborator

All 3 trials loaded